- Aura will Participate in the Research Forum at the 40th Annual European Association of Urology Congress
- Aura will Host a Virtual Urologic Oncology Investor Event Featuring Key Opinion Leaders at 4:30 pm Eastern Time on March 24, 2025
The EAU late-breaker presentation details are as follows:
Title: Safety and efficacy of Bel-sar (AU-011), a Virus-like-Drug-Conjugate (VDC), in patients with Non-Muscle Invasive Bladder Cancer (NMIBC)
Presenter: Seth Lerner, MD, Scott Department of Urology, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA
Date/Time: Saturday, March 22, 2025, from 3:30 pm to 3:35 pm Central European Standard Time (10:30 am to 10:45 am Eastern Time)
The EAU Research Forum details are as follows:
Title: Virus-like Drug Conjugates (VDC), a paradigm shifting approach for the treatment of bladder cancer: Mechanism, First Insights, and Future Directions
Presenters and Moderator: Shahrokh F. Shariat, MD, Dept. of Urology, Medical University of Vienna, Vienna, Austria; Laura Bukavina, MD, Glickman Urological Institute Cleveland Clinic Cleveland, OH, USA; Peter Black, MD, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada; Sabine D. Brookman-May, MD, Aura Biosciences, Boston, MA, USA; Dept. of Urology, University of Munich, LMU, Munich, Germany
Date/Time: Sunday, March 23, 2025, from 12:30 pm to 12:45 pm Central European Standard Time (7:30 am to 7:45 am Eastern Time)
Virtual urologic oncology investor event on Monday, March 24, 2025, at 4:30 pm Eastern Time
Aura will host a virtual urologic oncology investor event featuring Neal Shore, MD, FACS (Carolina Urologic Research Center), Gary Steinberg, MD, FACS (Rush University) and Jennifer A. Linehan, MD (Saint John’s Cancer Institute), who will join company management to discuss additional data from the ongoing Phase 1 trial in NMIBC, a multi-center, open-label clinical trial designed as a window of opportunity study to assess the safety and feasibility of local administration of bel-sar as a monotherapy prior to transurethral resection of bladder tumor (TURBT), the standard of care procedure. The study is designed to evaluate different approaches to optimize the feasibility of local administration and includes histopathological evaluation after a single dose to assess bel-sar’s biological activity and dual mechanism of action including the characterization of the immune response.
At the event, Aura will also provide a bladder cancer program update, including the planned Phase 1b/2 trial expansion and future development plans. A live question and answer session will follow the discussion. To register for the event, click here.
The live webcast of Aura’s virtual urologic oncology investor event will be available on the “Investors & Media” page under the “Events & Presentations” section of Aura’s website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of the webcast will be archived for 90 days following the presentation date.
Source: Aura Biosciences, Inc. (2025). Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress [Press release]. https://ir.aurabiosciences.com/news-releases/news-release-details/aura-biosciences-announces-additional-data-ongoing-phase-1-trial.